These medications, including semaglutides like Ozempic, are commonly used in the treatment of type 2 diabetes and obesity
Researchers matched participants using statistical techniques to account for differences in age, health conditions, and other factors that might skew results
In the US, GLP-1 spending rose from $13 to $72 billion in just five years, making approval tough for patients without diabeteseven as data for arthritis risk and cardiovascular benefits grow
It's creating entirely new purchase priorities and exposing category adjacencies no one was modeling
Why these drugs might be able to treat many of these neurological and psychiatric conditions is unclear, but finding out how exactly they work could help us better understand the body-and-mind connection and treat millions of people worldwide
The emerging research on cagrilintide combined with semaglutide (CagriSema) represents one such approach, adding amylin receptor agonism to GLP-1 for enhanced results